KemPharm, Inc. KMPH
5.81 +5.81
Day range unavailable
52-week range unavailable
Analyst view
Consensus: buy
Buy
Price target (mean) 22.33 +284.3% upside
Now 5.81
- Target (low)
- 19.00
- Target (mean)
- 22.33
- Target (high)
- 28.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 3
- 2 months ago 3
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.17 | -0.19 – -0.14 | -0.08 | -112.5% | 3.20M | +23.9% | 3 |
| Next quarter | -0.15 | -0.15 – -0.15 | -0.05 | -200.0% | 3.90M | -1.6% | 1 |
| Current year | -1.10 | -1.13 – -1.04 | -0.29 | -279.3% | 11.33M | -60.5% | 3 |
| Next year | -0.68 | -1.10 – -0.37 | -1.10 | +38.2% | 18.40M | +62.4% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 17, 2022 | Cantor Fitzgerald | Initiated | — | Overweight |
| Sep 15, 2022 | Canaccord Genuity | Initiated | — | Buy |
| Aug 17, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Jan 31, 2022 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Apr 9, 2021 | HC Wainwright & Co. | Maintained | — | Neutral |
| Mar 4, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jan 25, 2021 | Roth Capital | Initiated | — | Buy |
| May 20, 2020 | HC Wainwright & Co. | Reiterated | — | Buy |
| Nov 20, 2019 | H.C. Wainwright | Reiterated | — | Buy |
| Sep 5, 2019 | Roth Capital | Downgrade | Buy | Neutral |
| Jun 19, 2019 | H.C. Wainwright | Initiated | — | Buy |
| May 23, 2018 | Janney Capital | Initiated | — | Buy |
| Feb 26, 2018 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 18, 2015 | Oppenheimer | Maintained | — | Outperform |
| Jul 2, 2015 | Canaccord Genuity | Maintained | — | Buy |
| Jun 15, 2015 | Canaccord Genuity | Maintained | — | Buy |
| May 11, 2015 | Oppenheimer | Initiated | — | Outperform |
| May 11, 2015 | RBC Capital | Initiated | — | Outperform |